Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages
Open Access
- 12 February 2020
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 29 (155), 190052
- https://doi.org/10.1183/16000617.0052-2019
Abstract
Liquid biopsy refers to the analysis of any tumour-derived material circulating in the blood or any other body fluid. This concept is particularly relevant in lung cancer as the tumour is often difficult to reach and may need an invasive and potentially harmful procedure. Moreover, the multitude of anticancer drugs and their sequential use underline the importance of conducting an iterative assessment of tumour biology. Liquid biopsies can noninvasively detect any targetable genomic alteration and guide corresponding targeted therapy, in addition to monitoring response to treatment and exploring the genetic changes at resistance, overcoming spatial and temporal heterogeneity. In this article, we review the available data in the field, which suggest the potential of liquid biopsy in the area of lung cancer, with a particular focus on cell-free DNA and circulating tumour cells. We discuss their respective applications in patient selection and monitoring through targeted therapy, as well as immune checkpoint inhibitors. The current data and future applications of liquid biopsy in the early stage setting are also investigated. Liquid biopsy has the potential to help manage nonsmall cell lung cancer throughout all stages of lung cancer: screening, minimal residual disease detection to guide adjuvant treatment, early detection of relapse, systemic treatment initiation and monitoring of response (targeted or immune therapy), and resistance genotyping.This publication has 133 references indexed in Scilit:
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- Malignant cells facilitate lung metastasis by bringing their own soilProceedings of the National Academy of Sciences of the United States of America, 2010
- Collective cell migration in morphogenesis, regeneration and cancerNature Reviews Molecular Cell Biology, 2009
- Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized TrialClinical Cancer Research, 2008
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsThe New England Journal of Medicine, 2008
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinibBritish Journal of Cancer, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerThe New England Journal of Medicine, 2004